|

Sintilimab injection Clinical Trials

4 actively recruiting trials

Also known as: Sintilimab

Pipeline

Phase 1/2: 3

Top Sponsors

  • Zhejiang University1
  • Wu Wenming1
  • RemeGen Co., Ltd.1
  • Akeso1

Indications

  • Cancer4
  • Liver Disease1
  • Advanced Solid Tumours1
  • Advanced Intrahepatic Cholangiocarcinoma1
  • Pancreatic Cancer1

Other4 trials

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
Phase 1/2
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Phase 1/2
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.